Legal Opinion
In re Neurontin Marketing & Sale Practices Litigation
District Court, D. Massachusetts
Decided August 29, 2007No. MDL Docket No. 1629; Civil Action No. 04-10981PublishedCited by 20 opinions
1Opinion of the Court
MEMORANDUM AND ORDER
SARIS, District Judge.
In this proposed nationwide class action, plaintiffs allege that defendants Warner-Lambert and Pfizer engaged in a fraudulent scheme to promote and sell the drug Neuron-tin for “off-label” conditions. A condition is “off-label” if the Food and Drug Administration (“FDA”) has not approved Neurontin for that condition. Plaintiffs seek to certify a nationwide class of all consumers and Third Party Payors (“TPPs”) who have purchased Neurontin for “off-label” conditions. The proposed class period is from January 1,1994 through December 31, 2004, when a…
2Cases cited45 opinions
- Amchem Products, Inc. v. WindsorSupreme Court of the United States · 1997
- Sedima, S. P. R. L. v. Imrex Co.Supreme Court of the United States · 1985
- Eisen v. Carlisle & JacquelinSupreme Court of the United States · 1974
- Holmes v. Securities Investor Protection CorporationSupreme Court of the United States · 1992
- Hanlon v. Chrysler Corp.Court of Appeals for the Ninth Circuit · 1998
40 more not listed; retrieve them via the Exa API.
3Cited by20 opinions
- In re Pharmaceutical Industry Average Wholesale Price LitigationDistrict Court, D. Massachusetts · 2008
- In Re Neurontin Marketing, Sales Practices, & Products Liability LitigationDistrict Court, D. Massachusetts · 2009
- Garcia v. E.J. Amusements of New Hampshire, Inc.District Court, D. Massachusetts · 2015
- Clark v. PFIZER INC.Superior Court of Pennsylvania · 2010
- In re TJX Companies Retail Security Breach LitigationDistrict Court, D. Massachusetts · 2007
15 more not listed; retrieve them via the Exa API.